Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Author Correction: Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase.

Autor: Baltgalvis KA; Vividion Therapeutics, San Diego, CA, USA., Lamb KN; Vividion Therapeutics, San Diego, CA, USA., Symons KT; Vividion Therapeutics, San Diego, CA, USA., Wu CC; Vividion Therapeutics, San Diego, CA, USA., Hoffman MA; Vividion Therapeutics, San Diego, CA, USA., Snead AN; Vividion Therapeutics, San Diego, CA, USA., Song X; Vividion Therapeutics, San Diego, CA, USA., Glaza T; Vividion Therapeutics, San Diego, CA, USA., Kikuchi S; Vividion Therapeutics, San Diego, CA, USA., Green JC; Vividion Therapeutics, San Diego, CA, USA., Rogness DC; Vividion Therapeutics, San Diego, CA, USA., Lam B; Vividion Therapeutics, San Diego, CA, USA., Rodriguez-Aguirre ME; Vividion Therapeutics, San Diego, CA, USA., Woody DR; Vividion Therapeutics, San Diego, CA, USA., Eissler CL; Vividion Therapeutics, San Diego, CA, USA., Rodiles S; Vividion Therapeutics, San Diego, CA, USA., Negron SM; Vividion Therapeutics, San Diego, CA, USA., Bernard SM; Vividion Therapeutics, San Diego, CA, USA., Tran E; Vividion Therapeutics, San Diego, CA, USA., Pollock J; Vividion Therapeutics, San Diego, CA, USA., Tabatabaei A; Vividion Therapeutics, San Diego, CA, USA., Contreras V; Vividion Therapeutics, San Diego, CA, USA., Williams HN; Vividion Therapeutics, San Diego, CA, USA., Pastuszka MK; Vividion Therapeutics, San Diego, CA, USA., Sigler JJ; Vividion Therapeutics, San Diego, CA, USA., Pettazzoni P; Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Rudolph MG; Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Classen M; Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Brugger D; Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Claiborne C; Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Plancher JM; Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Cuartas I; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain., Seoane J; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain., Burgess LE; Vividion Therapeutics, San Diego, CA, USA., Abraham RT; Vividion Therapeutics, San Diego, CA, USA.; Odyssey Therapeutics, San Diego, CA, USA., Weinstein DS; Vividion Therapeutics, San Diego, CA, USA., Simon GM; Vividion Therapeutics, San Diego, CA, USA., Patricelli MP; Vividion Therapeutics, San Diego, CA, USA. mattp@vividion.com., Kinsella TM; Vividion Therapeutics, San Diego, CA, USA. tkinsella71c@gmail.com.

Publikováno v: Nature [Nature] 2024 Jul; Vol. 631 (8021), pp. E12.